Business
When Doug Ingram became Sarepta Therapeutics’ CEO in 2017, he didn’t have a connection to muscular dystrophy, but he has developed a fierce passion for the therapeutic area. He will step aside from his role to dedicate more time to his family.
FEATURED STORIES
Eli Lilly’s win in a head-to-head trial drove Novo Nordisk’s market cap to pre-Wegovy levels not long after the victor became the first pharma company to top a $1 trillion valuation. It seems one company can do no right, while the other can do no wrong.
Corsera Health’s Chief Operating Officer Rena Denoncourt and CFO Meredith Kaya speak with BioSpace about the biotech’s mission and vision for the next generation of cardiovascular care.
Billions of dollars’ worth of cancer drugs are discarded each year. Manufacturers must refund Medicare for some of this waste. A data-driven approach offers a practical path to greater efficiency.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Biopharmaceutical firm Alvotech Holdings announced merger plans with Oaktree Acquisition Corp. in a deal that will create a combined entity worth around $2.25 billion.
Ionis will manufacture and supply the drug for ongoing trials and process qualifications, while AstraZeneca will handle the commercial supply of eplontersen.
vTv Therapeutics said that the funds it saves through this process will allow it to focus on the Phase III development of TP399 and the company’s future growth.
Life sciences investors are being anything but shy as the end of 2021 draws near. Here are a few companies that are still seeing cash come in the door as December gets underway.
Surrozen’s ethos is “CLIMB ON”. This catchy and focus-appropriate acronym stands for Collaborate, Lead, Innovate, Motivate and be Brave, Open and Nurturing.
NanoMosaic plans to use the funds raised to continue building its commercial infrastructure, developing its applications, and advancing diagnostic collaborative development programs.
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
The SEC announced charges against Usama Malik and his former live-in girlfriend Lauren S. Wood regarding an FDA decision during a trading black out.
IDRI is working with a newly-formed consortium to develop a next-gen COVID-19 vaccine that will be stable at routine temperatures and that may be able to confer immunity for a longer duration.
Tune claims TEMPO can rapidly target and adjust the epigenomic machinery, controlling gene expression and dictating how the DNA will be molded.